Personal Genome Diagnostics PlasmaSelect-R Liquid Biopsy
Personal Genome Diagnostics today announced the launch of its PlasmaSelect-R liquid biopsy test. The test analyzes genetic alterations in cancer using circulating cell-free tumor DNA that is present in plasma, reducing the need for tumor tissue specimens. It detects sequence alterations and translocations in 63 well-characterized genes that include all important known biologic and therapeutic cancer targets. PGD said that the test is currently intended for use by cancer drug researchers, but that it plans to launch a CLIA version for clinical applications later in 2015.